Intensity Therapeutics Inc
Intensity Therapeutics Inc (INTS) is a very small‑cap, clinical‑stage biopharmaceutical company focused on oncology-related drug delivery and immunotherapy approaches. With a market capitalisation of roughly $12.6m, the company is speculative and typically of interest to investors who follow early‑stage biotech. Key investor considerations include the development pipeline, upcoming clinical readouts or partnership announcements that can materially affect the share price, and the company’s cash position and ability to finance operations. As with most micro‑cap biotech names, shares can be highly volatile, thinly traded and susceptible to dilution if additional capital is required. Potential rewards — if clinical or regulatory milestones succeed — come with commensurate risks, including clinical failure, regulatory setbacks and financing risk. This summary is general educational information only and not personal investment advice; suitability depends on your risk tolerance and financial situation.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Intensity Therapeutics stock with a target price of $6.25, indicating growth potential.
Financial Health
Intensity Therapeutics is maintaining moderate cash flow and book value per share, indicating stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring INTS
Social Media-Driven Short Squeeze Candidates
This collection features companies with high short interest that could potentially experience rapid price surges if targeted by retail investors on social media. Our analysts have carefully selected these stocks based on their similarity to recent phenomena like the Opendoor Technologies rally. These companies have the characteristics that often attract coordinated buying campaigns.
Published: July 18, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Platform technology potential
The company’s delivery‑focused platform is positioned to enhance oncology treatments if validated, though clinical proof is uncertain and outcomes may vary.
Clinical catalysts ahead
Trial readouts, partnerships or regulatory news can sharply move the share price; these events are binary and can lead to sizeable gains or losses.
Small‑cap considerations
A market cap around $12.6m implies limited liquidity and financing risk; investors should expect potential dilution and pronounced volatility.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
